A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia.

Am J Hematol · 2021 · PMC7894154 · PMID 33146922

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

We observed a strong trend of up‐regulation of activation markers and co‐stimulatory receptors (CD69, CD226, CD38, ICOS and 4‐1BB) on CD8 T cells post treatment of avelumab and decitabine.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.